Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 257 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pioglitazone HCl Clear all
Completed Phase 2 Interventional

Pioglitazone in Alzheimer Disease

NCT00982202
View directory record Official record
Conditions
Alzheimer Disease
Interventions
pioglitazone, Placebo
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
2
States / cities
Cleveland, Ohio • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 23, 2009 · Synced Oct 21, 2026, 2:23 PM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Type 2 Diabetes Mellitus

NCT01064687
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2189265, Exenatide, Placebo, Metformin, Pioglitazone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
78
States / cities
Goodyear, Arizona • Phoenix, Arizona • Cathedral City, California + 75 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 21, 2026, 2:23 PM EDT
Completed Phase 2 Interventional Results available

Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL

NCT00300365
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Pioglitazone, Placebo, Niacin ER, Aspirin
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Oct 21, 2026, 2:23 PM EDT
Completed Phase 4 Interventional

Pioglitazone in Hepatitis C

NCT00189163
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Pioglitazone, Placebo Oral Tablet
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 21, 2026, 2:23 PM EDT
Completed Phase 2 Interventional Results available

Treating Nonalcoholic Steatohepatitis With Pioglitazone

NCT00062764
View directory record Official record
Conditions
Hepatitis
Interventions
Actos (Pioglitazone)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Oct 21, 2026, 2:23 PM EDT
Withdrawn Not applicable Interventional

Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients

NCT01695707
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pioglitazone, Placebo (for pioglitazone)
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 21, 2026, 2:23 PM EDT
Completed Phase 2 Interventional

Study In People With Type 2 Diabetes

NCT00196989
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Pioglitazone, GW677954
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
69
States / cities
Birmingham, Alabama • Northport, Alabama • Chandler, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 21, 2026, 2:23 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes

NCT01289990
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 10773, Placebo, Sitagliptin 100mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
40
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Oct 21, 2026, 2:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ketosis Prone Diabetes in African-Americans

NCT00426413
View directory record Official record
Conditions
Ketosis Prone Diabetes, Diabetic Ketoacidosis, Severe Hyperglycemia
Interventions
pioglitazone
Drug
Lead sponsor
Emory University
Other
Eligibility
19 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Oct 21, 2026, 2:23 PM EDT
Completed Phase 1 Interventional

A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors

NCT02133625
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
carboplatin, pioglitazone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 21, 2026, 2:23 PM EDT
Completed Phase 1 Interventional

Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes Mellitus

NCT01082120
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
AZD1656, Pioglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2010 · Synced Oct 21, 2026, 2:23 PM EDT
Completed Phase 2 Interventional Results available

A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator

NCT00760578
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Placebo, Pioglitazone, MSDC-0160 90 mg, MSDC-0160 220 mg
Drug
Lead sponsor
Metabolic Solutions Development Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Los Angeles, California • Miami Gardens, Florida • West Palm Beach, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 21, 2026, 2:23 PM EDT
Completed Phase 3 Interventional

Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes

NCT00106808
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Muraglitazar, Pioglitazone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
112
States / cities
Birmingham, Alabama • Columbiana, Alabama • Madison, Alabama + 109 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2010 · Synced Oct 21, 2026, 2:23 PM EDT
Completed Phase 1 Interventional

Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis

NCT03231033
View directory record Official record
Conditions
Autoimmune Pulmonary Alveolar Proteinosis
Interventions
Pioglitazone
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 21, 2026, 2:23 PM EDT
Completed Early Phase 1 Interventional

Brown Fat Activation Study

NCT02919176
View directory record Official record
Conditions
Obese, Metabolic Syndrome
Interventions
Mirabegron, Pioglitazone, Mirabegron and Pioglitazone
Drug
Lead sponsor
Philip Kern
Other
Eligibility
35 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 21, 2026, 2:23 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus

NCT00722917
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
TAK-379, Pioglitazone, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Artesia, California • Norwalk, California • Santa Ana, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Oct 21, 2026, 2:23 PM EDT
Completed Phase 2 Interventional Results available

Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome

NCT00671515
View directory record Official record
Conditions
Depressive Disorder, Major, Metabolic Syndrome X
Interventions
Pioglitazone
Drug
Lead sponsor
Joseph Calabrese, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Oct 21, 2026, 2:23 PM EDT
Terminated Phase 4 Interventional Results available

Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections

NCT00742326
View directory record Official record
Conditions
HIV, Hepatitis C, Liver Disease, Fatty Liver, Steatosis
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 9, 2016 · Synced Oct 21, 2026, 2:23 PM EDT
Terminated Phase 3 Interventional

Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone

NCT01089790
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dutogliptin, Sitagliptin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 86 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
149
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 121 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2011 · Synced Oct 21, 2026, 2:23 PM EDT
Terminated Phase 2 Interventional Results available

Role of Proinflammatory Signaling in Alcohol Craving

NCT01631630
View directory record Official record
Conditions
Alcohol Dependence, Alcohol Drinking, Stress, Alcohol-Related Disorders
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 21, 2026, 2:23 PM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 21, 2026, 2:23 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Ghrelin Regulation and Structure: Effect of Thiazolidinedione Therapy on Ghrelin

NCT00843791
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
placebo, pioglitazone
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 21, 2026, 2:23 PM EDT
Completed Phase 4 Interventional Results available

Pioglitazone in Patients With Mood Disorders

NCT01559857
View directory record Official record
Conditions
Major Depressive Disorder, Insulin Resistance
Interventions
Pioglitazone, Sugar Pill
Drug
Lead sponsor
Stanford University
Other
Eligibility
20 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 21, 2026, 2:23 PM EDT
Completed Phase 1 Interventional

Effect of Pioglitazone on Inflammation in Cystic Fibrosis

NCT00719381
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Pioglitazone
Drug
Lead sponsor
Paul Beringer
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Oct 21, 2026, 2:23 PM EDT